Chronic granulomatous disease: Difference between revisions

From IDWiki
(added DDx)
()
Line 10: Line 10:
==Clinical Manifestations==
==Clinical Manifestations==


*Recurrent infections with catalase-positive organisms, including [[Staphylococcus aureus]]
*Recurrent infections
**Catalase-positive organisms, including [[Staphylococcus aureus]], [[Burkholderia cepacia]], [[Serratia marcescens]], [[Nocardia species]], and [[Aspergillus species]]
*Highest-risk group for [[invasive aspergillosis]]
**CGD is the highest-risk group for [[invasive aspergillosis]]
*Granuloma formation, often in the GI and GU tracts and may precede other clinical symptoms


== Differential Diagnosis ==
==Differential Diagnosis==


* Other [[Primary immunodeficiency|primary immunodeficiencies]]
*Other [[Primary immunodeficiency|primary immunodeficiencies]]
** [[MPO deficiency]], which will have an abnormal DHR test but largely asymptomatic unless concurrent [[diabetes mellitus]]
**[[MPO deficiency]], which will have an abnormal DHR test but largely asymptomatic unless concurrent [[diabetes mellitus]]
** [[Hyper-IgE syndrome]], though ''Aspergillus'' will be more typically pulmonary
**[[Hyper-IgE syndrome]], though ''Aspergillus'' will be more typically pulmonary
** IRAK4/MyD88 deficiency, which won't have fungal infections and improves with age
**IRAK4/MyD88 deficiency, which won't have fungal infections and improves with age
** Humoral immunodeficiencies, such as [[CVID]] or [[Bruton tyrosine kinase deficiency]], though they tend to have more infections with encapsulated organisms and will have abnormal quantitative immunoglobulins
**Humoral immunodeficiencies, such as [[CVID]] or [[Bruton tyrosine kinase deficiency]], though they tend to have more infections with encapsulated organisms and will have abnormal quantitative immunoglobulins
* [[Inflammatory bowel disease]]
*[[Inflammatory bowel disease]]
* [[Cystic fibrosis]]
*[[Cystic fibrosis]]
* [[Sarcoidosis]]
*[[Sarcoidosis]]


== Diagnosis ==
==Diagnosis==


* The diagnosis is confirmed with the dihyohodamine-123 (DHR-123) test
*The diagnosis is confirmed with the dihyohodamine-123 (DHR-123) test


==Management==
==Management==
Line 36: Line 38:
**Possibly also [[interferon-γ]]
**Possibly also [[interferon-γ]]


== Further Reading ==
==Further Reading==


* Considerations in the Diagnosis of Chronic Granulomatous Disease. ''J Pediatric Infect Dis Soc''. 2018;7(S1):S6-S11. doi: [https://doi.org/10.1093/jpids/piy007 10.1093/jpids/piy007]
*Considerations in the Diagnosis of Chronic Granulomatous Disease. ''J Pediatric Infect Dis Soc''. 2018;7(S1):S6-S11. doi: [https://doi.org/10.1093/jpids/piy007 10.1093/jpids/piy007]


[[Category:Pediatrics]]
[[Category:Pediatrics]]

Revision as of 19:41, 15 August 2020

Background

Pathophysiology

  • Defect in NADPH oxidase
  • Therefore unable to generate superoxide radicals required by phagocytes to kill pathogens

Clinical Manifestations

Differential Diagnosis

Diagnosis

  • The diagnosis is confirmed with the dihyohodamine-123 (DHR-123) test

Management

Further Reading

  • Considerations in the Diagnosis of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc. 2018;7(S1):S6-S11. doi: 10.1093/jpids/piy007